Hypericin in cancer treatment: More light on the way

International Journal of Biochemistry and Cell Biology

Volumn 34, Issue 3, 2002, Pages 221-241

  Agostinis, Patrizia ^a   Vantieghem, Annelies ^a   Merlevede, Wilfried ^a   De Witte, Peter A M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Apoptosis; Hypericin; Mitochondria; Photodynamic theraphy; Signaling transduction

Indexed keywords

HYPERICIN; OXYGEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER THERAPY; CYTOTOXICITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFECT; HYPERICUM PERFORATUM; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; MOLECULAR MECHANICS; NECROSIS; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CYTOCHROME C GROUP; HELA CELLS; HUMANS; HYPERICUM; MICROSCOPY, FLUORESCENCE; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEOPLASMS; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

HYPERICUM; HYPERICUM PERFORATUM;

EID: 0036176587     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(01)00126-1     Document Type: Review

References (146)

1. Hypericism
2. Photosensitization: An investigation and review of the problem in cattle of South Texas
3. Hypericin and pseudohypericin in some Hypericum species
4. The chemical and biological properties of hypericin: A compound with a broad spectrum of biological activities
5. On the nature of soluble hypericin in Hypericum species
6. Seasonal variation in hypericin content of Hypericum perforatum L. (St. John's wort)
7. Photocytotoxicity of protohypericin after photoconversion to hypericin
8. Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady state administration of Hypericum perforatum extract (St. John's wort)
9. Single-dose and steady state administration of Hypericum perforatum extract St. John's wort does not influence skin sensitivity to UV radiation, visible light, and solar-simulated radiation
10. St. John's wort for depression-an overview and meta-analysis of randomised clinical trials
11. Comparison of St. John's wort and imipramine for treating depression: Randomised controlled trial
12. Hyperforin as a possible antidepressant component of Hypericum extracts
13. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract
14. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus
15. Kinetics and yield of singlet oxygen photosensitized by hypericin in organic and biological media
16. A compilation of singlet oxygen yields from biologically relevant molecules
17. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection
18. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in non-human primates
19. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: Aromatic polycyclic diones hypericin and pseudohypericin
20. Antiretroviral activity of synthetic hypericin and related analogs
21. Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses
22. Antiviral activity of the photoactive plant pigment hypericin
23. Chemiluminescent activation of the antiviral activity of hypericin: A molecular flashlight
24. Antiviral activities of hypericin
25. The importance of light in the anti-HIV effect of hypericin
26. Hypericin as an inactivator of infectious viruses in blood components
27. Inhibition of duck hepatitis B virus replication by hypericin
28. Phase I studies of hypericin, the active compound in St. John's wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258
29. Strategies for evaluation of enveloped virus inactivation in red cell concentrates using hypericin
30. Photodynamic therapy
31. Cylindrical fiberoptic light diffuser for medical applications
32. Photodynamic therapy in oncology: Mechanisms and clinical use
33. What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)?
34. Hypericin and pseudohypericin specifically inhibit protein kinase C: Possible relation to their antiretroviral activity
35. Inhibition of epidermal growth factor receptor tyrosine kinase activity by hypericin
36. Photosensitized inhibition of growth factor-regulated protein kinases by hypericin
37. Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells
38. The effect of hypericin and hypocrellin-A on lipid membranes and membrane potential of 3T3 fibroblasts
39. Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria
40. Photoactivation of hypericin generates singlet oxygen in mitochondria and inhibits succinoxidase
41. Effect of the antiretroviral agent hypericin on rat liver mitochondria
42. Different pathways mediate cytochrome c release after photodynamic therapy with hypericin
43. Targeted cross-linking of a molten globule form of acetylcholinesterase by the virucidal agent hypericin
44. Photooxidation of lens alpha-crystallin by hypericin (active ingredient in St. John's wort)
45. Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells
46. Photosensitization with anticancer agents. 17. EPR studies of photodynamic action of hypericin: Formation of semiquinone radical and activated oxygen species on illumination
47. Photodynamically-induced cytotoxicity of hypericin dye on human fibroblast cell line MRC5
48. Laser photosensitization of cells by hypericin
49. Hypericin: A potential antiglioma therapy
50. Effects of anthralin and hypericin on growth factor signalling and cell proliferation in vitro
51. Hypericin-induced phototoxicity in cultured fibroblasts and swine erythrocytes
52. Hypericin: A new laser phototargeting agent for human cancer cells
53. Differential cytotoxic effects induced after photosensitization by hypericin
54. Cytotoxicity and antiproliferative effect of hypericin and derivatives after photosensitization
55. A comparative study on the photocytotoxicity of hypericin on A431 cells using three different assays
56. Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: Implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders
57. Antioxidant enzyme response to hypericin in EMT6 mouse mammary carcinoma cells
58. Photodynamic activity of hypericin in human urinary bladder carcinoma cells
59. Hypericin photosensitization of tumor and metastatic cell lines of human prostate
60. Synergistic effect of photodynamic therapy with hypericin in combination with hyperthermia on loss of clonogenicity of RIF-1 cells
61. Photocytotoxicity of hypericin in oxic and hypoxic conditions
62. The role of oxygen in the antiviral activity of hypericin and hypocrellin
63. EPR studies of hypericin. Photogeneration of free radicals and superoxide
64. Hypericin-induced cell photosensitization involves an intracellular pH decrease
65. + exchanger
66. Photophysics of hypericin and hypocrellin A in complex with subcellular components: Interactions with human serum albumin
67. Is the excited state H-atom transfer in hypericin concerted?
68. The antiviral agent hypericin has in vitro activity against HSV-1 through non-specific association with viral and cellular membranes
69. Subcellular distributions and excited state processes of hypericin in neurons
70. Binding, uptake, and transport of hypericin, by Caco-2 cell monolayers
71. Specific interactions of antiretrovirally active drug hypericin with DNA as studied by surface-enhanced resonance raman spectroscopy
72. Sequence specific interaction of the antiretrovirally active drug hypericin with 5′ATGGCAGGATAT3′ oligonucleotide: A resonance Raman spectroscopy study
73. Sequence specific interaction of the photoactive drug hypericin depends on the structural arrangement and the stability of the structure containing its specific 5AG3 target: A resonance Raman spectroscopy study
74. The photobiology of photodynamic therapy: Cellular targets and mechanisms
75. The application of the micronucleus test in Chinese hamster V79 cells to detect drug-induced photogenotoxicity
76. Genotoxicity of a standardized Hypericum extract
77. More than one way to die: Apoptosis, necrosis and reactive oxygen damage
78. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
79. Mechanisms and functions of cell death
80. Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: Potential therapeutic application
81. Hypericin inhibits cell growth and induces apoptosis in retinal pigment epithelial cells: Possible involvement of protein kinase C
82. Growth inhibition and apoptosis in human neuroblastoma SK-N-SH cells induced by hypericin, a potent inhibitor of protein kinase C
83. Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of Bcl-2 expression, and does not require wild-type p53
84. Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis
85. The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin
86. Cellular photodestruction induced by hypericin in AY-27 rat bladder carcinoma cells
87. Overexpression of Bcl-2 does not protect cells from hypericin photoinduced mitochondrial membrane depolarization, but delays subsequent events in the apoptotic pathway
88. Hypericin photoinduced apoptosis involves the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activation of caspase-8
89. Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10
90. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen
91. The role of subcellular localization in initiation of apoptosis by photodynamic therapy
92. Signaling pathways in cell death and survival after photodynamic therapy
93. A photodynamic pathway to apoptosis and necrosis induced by dimethyl tetrahydroxyhelianthrone and hypericin in leukaemic cells: Possible relevance to photodynamic therapy
94. Bcl-2 family proteins
95. Apoptosis control by death and decoy receptors
96. Mitochondria and apoptosis
97. All along the watchtower: On the regulation of apoptosis regulators
98. Photodynamic therapy: A mitochondrial inducer of apoptosis
99. IAP family proteins: Suppressors of apoptosis
100. Target protease specificity of the viral serpin CrmA
101. Photodynamic therapy induces caspase-3 activation in HL-60 cells
102. Rapid cytochrome c release, activation of caspases-3, -6, -7 and -8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy
103. Protease activation and cleavage of poly(ADP-ribose) polymerase: An integral part of apoptosis in response to photodynamic therapy
104. Photodynamic therapy-induced apoptosis in lymphoma cells: Translocation of cytochrome c causes inhibition of respiration as well as caspase activation
105. Photodynamic therapy-induced death of MCF-7 human breast cancer cells: A role for caspase-3 in the late steps of apoptosis but not for the critical lethal event
106. Involvement of Fas (APO-1/CD95) during photodynamic-therapy-mediated apoptosis in human epidermoid carcinoma A431 cells
107. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis
108. Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model
109. Mitochondrial control of cell death
110. Bcl-2 overexpression blocks caspase activation and downstream events instigated by photodynamic therapy
111. L overexpression do not prevent early mitochondrial events but still depress caspase activity
112. Antisense Bcl-2 retrovirus vector increases the sensitivity of a human gastric adenocarcinoma cell line to photodynamic therapy
113. Involvement of Bcl-2
114. Enhanced apoptotic response to photodynamic therapy after Bcl-2 transfection
115. Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc4
116. L regulates the membrane potential and volume homeostasis of mitochondria
117. Distinct stages of cytochrome c release from mitochondria: Evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress-induced apoptosis
118. Caspase-12 mediates endoplasmic reticulum-specific apoptosis and cytotoxicity by amyloid-beta
119. Caspase-2 is localized at the Golgi complex and cleaves golgin-160 during apoptosis
120. Signal transduction through MAP kinase cascades
121. Making the connection: Coupling of stress-activated ERK/MAPK (extracellular-signal-regulated kinase/mitogen-activated protein kinase) core signalling modules to extracellular stimuli and biological responses
122. Promotion of photodynamic-induced apoptosis by stress kinases
123. Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative
124. Activation of JNK and p38 but not ERK MAP kinase in human skin cells by 5-aminolevulinate photodynamic therapy
125. Apoptotic signalling cascade in photosensitized human epidermal carcinoma A431 cells: Involvement of singlet oxygen, c-Jun N-terminal kinase, caspase-3 and p21-activated kinase-2
126. Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide: A methylester photosensitization
127. p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system
128. Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha-supported proliferation of leukemia and lymphoma cell lines
129. PDT efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model
130. Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo
131. Intratumoral hypericin and KTP laser therapy for transplanted squamous cell carcinoma
132. In vivo photodynamic activity of hypericin in transitional cell carcinoma bladder tumors
133. Efficacy of antitumoral photodynamic therapy with hypericin: Relationship between biodistribution and photodynamic effects in RIF-1 mouse tumor model
134. Photodynamic therapy with hypericin in a mouse P388 tumor model: Vascular effects determine the efficacy
135. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy
136. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy
137. A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice
138. Does tumor uptake of Foscan determine PDT efficacy?
139. Hypericin in phototherapy
140. Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin
141. Photodynamic therapeutics: Basic principles and clinical applications
142. + T cell-mediated cytotoxicity reaction by hypericin: Potential for treatment of T cell-mediated diseases
143. Excited state properties of hypericin: Electronic spectra and fluorescence decay kinetics
144. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin
145. Role of adhesion molecules in bladder cancer: An important part of the jigsaw